Bayers' CEO Says Rapidly Shifting to Life Sciences

The transcript discusses the company's strategic direction towards life sciences, progress in the third quarter, and the divestiture of Covestro. It covers the animal health business, its market position, and potential collaboration with Eli Lilly. The Monsanto acquisition and regulatory compliance are addressed, along with the funding structure and optimization strategies. The company is focused on executing its plans while considering regulatory timelines and market conditions.

What strategic direction is the company rapidly shifting towards?

• Technology

• Automotive

• Life Sciences

• Retail

How did the company strengthen its US Farm animal business?

• By increasing marketing spend

• By acquiring anti-trust assets

• By launching new products

• By acquiring a competitor

What is the company's current focus regarding potential mergers with Eli Lilly?

• Actively pursuing the merger

• Focusing on existing projects

• Reducing operational costs

• Exploring new markets

What is the company's approach to the regulatory challenges of the Monsanto acquisition?

• Ignoring regulatory requirements

• Preempting regulatory verdicts

• Aligning with regulatory timetables

• Delaying the acquisition

What is the significance of the BSF contract in the context of the Monsanto acquisition?

• It delays the acquisition

• It is unrelated to the acquisition

• It is a preliminary step

• It finalizes the acquisition

How has the currency exchange rate impacted the company's financial strategy?

• Negatively affected cash flow

• Positively impacted proceeds

• Increased operational costs

• Decreased market share

What is the company's stance on optimizing the funding structure?

• Reducing equity measures

• Increasing debt

• Open to optimization opportunities

• No changes planned